Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an anti-VEGF single-chain antibody for canine cancer therapy

Viruses

Volumn 7, Issue 7, 2015, Pages 4075-4092

  Adelfinger, Marion ^a   Bessler, Simon ^a   Frentzen, Alexa ^b   Cecil, Alexander ^a   Langbein Laugwitz, Johanna ^a   Gentschev, Ivaylo ^a,b   Szalay, Aladar A ^a,b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b GENELUX CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Antibody production; Cancer; Canine cancer cell lines; Canine cancer therapy; Canine soft tissue sarcoma (CSTS); Oncolytic virus

Indexed keywords

CD31 ANTIGEN; ONCOLYTIC VIRUS; VASCULOTROPIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER THERAPY; CONTROLLED STUDY; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; MICROSCOPY; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; VACCINIA VIRUS; VIRUS REPLICATION; WESTERN BLOTTING; ANIMAL; DOG DISEASES; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; VETERINARY;

GIARDIA LAMBLIA VIRUS; MUS; VACCINIA VIRUS;

ANIMALS; DOG DISEASES; DOGS; FEMALE; MICE; MICE, NUDE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SINGLE-CHAIN ANTIBODIES; VACCINIA VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84937396129     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7072811     Document Type: Article

References (37)

1. Animal Health Survey In Companion Animal News, Englewood Colorado. Morris Animal Foundation, 1998 and 2005.
2. Merlo, D.F.; Rossi, L.; Pellegrino, C.; Ceppi, M.; Cardellino, U.; Capurro, C.; Ratto, A.; Sambucco, P.L.; Sestito, V.; Tanara, G.; et al. Cancer incidence in pet dogs: Findings of the Animal Tumor Registry of Genoa, Italy. J. Vet. Intern. Med. 2008, 22, 976–984. [CrossRef] [PubMed]
3. Hansen, K.; Khanna, C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur. J. Cancer 2004, 40, 858–880. [CrossRef] [PubMed]
4. Kelsey, J.L.; Moore, A.S.; Glickman, L.T. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol. Rev. 1998, 20, 204–217. [CrossRef] [PubMed]
5. Patil, S.S.; Gentschev, I.; Nolte, I.; Ogilvie, G.; Szalay, A.A. Oncolytic virotherapy in veterinary medicine: Current status and future prospects for canine patients. J. Transl. Med. 2012, 10, e3 [CrossRef] [PubMed]
6. Gentschev, I.; Patil, S.S.; Petrov, I.; Cappello, J.; Adelfinger, M.; Szalay, A.A. Oncolytic virotherapy of canine and feline cancer. Viruses 2014, 6, 2122–2137. [CrossRef] [PubMed]
7. Gentschev, I.; Patil, S.S.; Adelfinger, M.; Weibel, S.; Geissinger, U.; Frentzen, A.; Chen, N.G.; Yu, Y.A.; Zhang, Q.; Ogilvie, G.; et al. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 2013, 4, 84–89. [CrossRef] [PubMed]
8. Buckel, L.; Advani, S.J.; Frentzen, A.; Zhang, Q.; Yu, Y.A.; Chen, N.G.; Ehrig, K.; Stritzker, J.; Mundt, A.J.; Szalay, A.A. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium. Int. J. Cancer 2013, 133, 2989–2999. [CrossRef] [PubMed]
9. Frentzen, A.; Yu, Y.A.; Chen, N.; Zhang, Q.; Weibel, S.; Raab, V.; Szalay, A.A. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl. Acad. Sci. USA 2009, 106, 12915–12920. [CrossRef] [PubMed]
10. Patruno, R.; Arpaia, N.; Gadaleta, C.D.; Passantino, L.; Zizzo, N.; Misino, A.; Lucarelli, N.M.; Catino, A.; Valerio, P.; Ribatti, D.; et al. VEGF concentration from plasma-activated platelets rich correlates with microvascular density and grading in canine mast cell tumour spontaneous model J. Cell. Mol. Med. 2009, 13, 555–561. [CrossRef] [PubMed]
11. Rossmeisl, J.H.; Duncan, R.B.; Huckle, W.R.; Troy, G.C. Expression of vascular endothelial growth factor in tumors and plasma from dogs with primary intracranial neoplasms. Am. J. Vet. Res. 2007, 68, 1239–1245. [CrossRef] [PubMed]
12. Sobczynska-Rak, A.; Polkowska, I.; Silmanowicz, P. Elevated vascular endothelial growth factor (VEGF) levels in the blood serum of dogs with malignant neoplasms of the oral cavity. Acta Vet Hung. 2014, 62, 362–371. [CrossRef] [PubMed]
13. Zizzo, N.; Patruno, R.; Zito, F.A.; di Summa, A.; Tinelli, A.; Troilo, S.; Misino, A.; Ruggieri, E.; Goffredo, V.; Gadaleta, C.D.; et al. Vascular endothelial growth factor concentrations from platelets correlate with tumor angiogenesis and grading in a spontaneous canine non-Hodgkin lymphoma model. Leuk. Lymphoma 2010, 51, 291–296. [CrossRef] [PubMed]
14. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669–676.
15. [CrossRef] [PubMed]
16. Ferrara, N.; Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 2005, 438, 967–974 [CrossRef] [PubMed]
17. Folkman, J. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov 2007, 6, 273–286. [CrossRef] [PubMed]
18. 17. Patil, S.S.; Gentschev, I.; Adelfinger, M.; Donat, U.; Hess, M.; Weibel, S.; Nolte, I.; Frentzen, A.; Szalay, A.A. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS ONE 2012, 7, e47472. [CrossRef] [PubMed]
19. Sterenczak, K.A.; Willenbrock, S.; Barann, M.; Klemke, M.; Soller, J.T.; Eberle, N.; Nolte, I.; Bullerdiek, J.; Murua Escobar, H. Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms Gene 2009, 434, 35–42. [CrossRef] [PubMed]
20. Gentschev, I.; Ehrig, K.; Donat, U.; Hess, M.; Rudolph, S.; Chen, N.; Yu, Y.A.; Zhang, Q.; Bullerdiek, J.; Nolte, I.; et al. Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J. Oncol. 2010, 2010, e736907. [CrossRef] [PubMed]
21. Murua Escobar, H.; Meyer, B.; Richter, A.; Becker, K.; Flohr, A.M.; Bullerdiek, J.; Nolte, I Molecular characterization of the canine HMGB1. Cytogenet. Genome Res. 2003, 101, 33–38 [CrossRef] [PubMed]
22. Gentschev, I.; Stritzker, J.; Hofmann, E.; Weibel, S.; Yu, Y.A.; Chen, N.; Zhang, Q.; Bullerdiek, J.; Nolte, I.; Szalay, A.A. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: Preclinical development of a therapeutic agent. Cancer Gene Ther. 2009, 16, 320–328 [CrossRef] [PubMed]
23. Fork, M.A.; Murua Escobar, H.; Soller, J.T.; Sterenczak, K.A.; Willenbrock, S.; Winkler, S.; Dorsch, M.; Reimann-Berg, N.; Hedrich, H.J.; Bullerdiek, J.; et al. Establishing an in vivo model of canine prostate carcinoma using the new cell line CT1258. BMC Cancer 2008, 8, e240. [CrossRef] [PubMed]
24. Cecil, A.; Gentschev, I.; Adelfinger, M.; Nolte, I.; Dandekar, T.; Szalay, A.A. Antigen profiling analysis of vaccinia virus injected canine tumors: Oncolytic virus efficiency predicted by boolean models. Bioengineered 2014, 5, 319–325.
25. 24[CrossRef] [PubMed] . Gentschev, I.; Adelfinger, M.; Josupeit, R.; Rudolph, S.; Ehrig, K.; Donat, U.; Weibel, S.; Chen, N.G.; Yu, Y.A.; Zhang, Q.; et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS ONE 2012, 7, e37239. [CrossRef] [PubMed]
26. Adelfinger, M.; Gentschev, I.; Grimm de Guibert, J.; Weibel, S.; Langbein-Laugwitz, J.; Hartl, B.; Murua Escobar, H.; Nolte, I.; Chen, N.G.; Aguilar, R.J.; et al. Evaluation of a New Recombinant Oncolytic Vaccinia Virus Strain GLV-5b451 for Feline Mammary Carcinoma Therapy. PLoS ONE 2014, 9, e104337.
27. [CrossRef] [PubMed]
28. De Queiroz, G.F.; Dagli, M.L.; Fukumasu, H.; Zavala, A.A.; Matera, J.M. Vascular endothelial growth factor expression and microvascular density in soft tissue sarcomas in dogs. J. Vet. Diagn Investig. 2010, 22, 105–108. [CrossRef]
29. Dvorak, H.F.; Nagy, J.A.; Feng, D.; Brown, L.F.; Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 1999, 237, 97–132. [PubMed]
30. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: Therapeutic perspective. Clin. Cancer Res. 2006, 12, 5018–5022. [CrossRef] [PubMed]
31. Braghiroli, M.I.; Sabbaga, J.; Hoff, P.M. Bevacizumab: Overview of the literature. Expert Rev Anticancer Ther. 2012, 12, 567–580. [CrossRef] [PubMed]
32. Meadows, K.L.; Hurwitz, H.I. Anti-VEGF therapies in the clinic. Cold Spring Harb. Perspect Med. 2012, 2. [CrossRef] [PubMed]
33. Jain, R.K. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia Cancer Cell 2014, 26, 605–622. [CrossRef] [PubMed]
34. Jain, R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev 2001, 46, 149–168. [CrossRef]
35. Gholami, S.; Marano, A.; Chen, N.G.; Aguilar, R.J.; Frentzen, A.; Chen, C.H.; Lou, E.; Fujisawa, S.; Eveno, C.; Belin, L.; et al. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer. Breast Cancer Res. Treat 2014, 148, 489–499. [CrossRef] [PubMed]
36. Hiley, C.T.; Chard, L.S.; Gangeswaran, R.; Tysome, J.R.; Briat, A.; Lemoine, N.R.; Wang, Y Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. J. Virol. 2013, 87, 2781–2790. [CrossRef] [PubMed]
37. Weibel, S.; Hofmann, E.; Basse-Luesebrink, T.C.; Donat, U.; Seubert, C.; Adelfinger, M.; Gnamlin, P.; Kober, C.; Frentzen, A.; Gentschev, I.; et al. Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer. J. Transl Med. 2013, 11, e106. [CrossRef] [PubMed]